Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. by Abubakar, M et al.
 1 
 
 
Prognostic value of automated KI67 scoring in breast cancer: a 
centralised evaluation of 8,088 patients from 10 study groups.  
 
Authors 
Mustapha Abubakar
1 
(Mustapha.Abubakar@icr.ac.uk); Nick Orr
2
 (Nicholas.Orr@icr.ac.uk); Frances 
Daley
2
 (Frances.Daley@icr.ac.uk); Penny Coulson
1
 (Penny.Coulson@icr.ac.uk); H Raza Ali
3
 
(Raza.Ali@cruk.cam.ac.uk); Fiona Blows
4
 (fmb28@medschl.cam.ac.uk); Javier Benitez
5,6
 
(jbenitez@cnio.es); Roger Milne
7,8
 (Roger.Milne@cancervic.org.au); Herman Brenner
9,10,11
 
(h.brenner@dkfz.de); Christa Stegmaier
12
 (c.stegmaier@soziales.saarland.de);  Arto Mannermaa
13,14
 
(arto.mannermaa@uef.fi); Jenny Chang-Claude
15,16
 (j.chang-claude@dkfz-heidelberg.de);  Anja 
Rudolph
15
 (a.rudolph@dkfz-heidelberg.de); Peter Sinn
17
 (Peter.Sinn@med.uni-heidelberg.de); Fergus 
J Couch
18
 (Couch.Fergus@mayo.edu); Peter Devilee
19
 (p.devilee@lumc.nl); Rob AEM Tollenaar
20
 
(R.A.E.M.Tollenaar@lumc.nl); Caroline Seynaeve
21
 (c.seynaeve@erasmusmc.nl); Jonine Figueroa
22
  
(Jonine.figueroa@ed.ac.uk); Mark E Sherman
23
 (shermans@mail.nih.gov); Jolanta Lissowska
24
 
(lissowsj@coi.waw.pl); Stephen Hewitt
25
 (hewitts@mail.nih.gov); Diana Eccles
26
 
(D.M.Eccles@soton.ac.uk); Maartje J Hooning
27
 (m.hooning@erasmusmc.nl); Antoinette 
Hollestelle
27
 (a.hollestelle@erasmusmc.nl); John WM Martens
27
 (j.martens@erasmusmc.nl); Carolien 
HM van Deurzen
28
 (c.h.m.vandeurzen@erasmusmc.nl); kConFab Investigators
29
 
(heather.thorne@petermac.org); Manjeet K Bolla
30
 (mkh39@medschl.cam.ac.uk); Qin Wang
30
 
(qw232@medschl.cam.ac.uk); Michael Jones
1
 (Michael.Jones@icr.ac.uk); Minouk Schoemaker
1
 
(Minouk.Schoemaker@icr.ac.uk); Jelle Wesseling
31
 (j.wesseling@nki.nl); Flora E van Leeuwen
32
 
(f.v.leeuwen@nki.nl); Laura Van ‘t Veer31 (Laura.Vantveer@ucsf.edu); Douglas Easton4,30 
(dfe20@medschl.cam.ac.uk); Anthony J Swerdlow
1,33
 (Anthony.Swerdlow@icr.ac.uk); Mitch 
Dowsett
2,34
 (Mitchell.Dowsett@icr.ac.uk); Paul D Pharoah
4,30
 (pp10001@medschl.cam.ac.uk); 
Marjanka K Schmidt
31,32
 (mk.schmidt@nki.nl) and Montserrat Garcia-Closas
23 (montserrat.garcia-
closas@nih.gov).  
  
Author affiliations  
1 
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK 
2 
Breast Cancer Now Toby Robins Research Centre, Division of Breast Cancer Research, The Institute 
of Cancer Research, London, UK 
3 
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK 
4 
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, 
Cambridge, UK 
 2 
 
 
5 
Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research 
Centre (CNIO), Madrid, Spain 
6 
Centro de Investigacion en Red de Enfermedades Raras (CIBERER), Valencia, Spain 
7 
Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia 
8 
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global health, The 
University of Melbourne, Melbourne, Australia 
9
 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 
Heidelberg, Germany  
10 
Division of Preventive Oncology, German Cancer Research Center (DKFZ), and National Center 
for Tumor Diseases (NCT), Heidelberg, Germany 
11 
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, 
Germany 
12 
Saarland Cancer Registry, Saarland, Germany 
13 
School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, Cancer 
Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland 
14 
Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland 
15 
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany 
16 
University Cancer Center Hamburg , University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany 
17 
Department of Pathology, Institute of Pathology, Heidelberg University Hospital, Germany  
18 
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA 
19 
Department of Human Genetics & Department of Pathology, Leiden University Medical Center, 
Leiden, The Netherlands 
20 
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands 
21 
Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, 
The Netherlands 
22 
Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, 
Scotland, UK 
23 
Divisions of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, 
USA 
24
 Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer 
Center and Institute of Oncology, Warsaw, Poland  
25
 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Rockville, MD, 
USA  
26 
Faculty of Medicine Academic Unit of Cancer Sciences, Southampton General Hospital, 
Southampton, UK 
 3 
 
 
27 
Family Cancer Clinic, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, 
The Netherlands 
28 
Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands 
29 
Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia 
30
 Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, 
University of Cambridge, Cambridge, UK 
31 
Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 
Amsterdam, The Netherlands 
32
 Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van 
Leeuwenhoek Hospital, Amsterdam, The Netherlands 
33
 Division of Breast Cancer Research, The Institute of Cancer Research, London, UK 
34
 Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London 
 
 
Corresponding author 
Mustapha Abubakar 
Division of Genetics and Epidemiology 
Institute of Cancer Research  
15 Cotswold Road, Sutton, London, SM2 5NG 
United Kingdom  
Email: Mustapha.Abubakar@icr.ac.uk  
 4 
 
 
Abstract  
Background: The value of KI67 in breast cancer prognostication has been questioned due to concerns 
on the analytical validity of visual KI67 assessment and methodological limitations of published 
studies. Here, we investigate the prognostic value of automated KI67 scoring in a large, multi-centre 
study, and compare this with pathologists’ visual scores available in a subset of patients. 
Methods: We utilised 143 tissue microarrays (TMAs) containing 15,313 tumour tissue cores from 
8,088 breast cancer patients from 10 collaborating studies. A total of 1,401 deaths occurred during a 
median follow-up of 7.5 years. Centralised KI67 assessment was performed using an automated 
scoring protocol. The relationship of KI67 levels with 10-year breast cancer specific survival (BCSS) 
was investigated using Kaplan-Meier survival curves and in Cox proportional hazard regression 
models adjusted for known prognostic factors.  
Results: Patients in the highest quartile of KI67 (>12% positive KI67 cells) had a worse 10-year 
BCSS than patients in the lower three quartiles. This association was statistically significant for ER 
positive [Hazard ratio (HR) at baseline = 1.96 (1.31 – 2.93); P= 0.001] but not for ER negative [1.23 
(0.86 – 1.77); P= 0.248] patients (P-heterogeneity= 0.064). In spite of differences in characteristics of 
the study populations, the estimates of HR were consistent across all studies (P-heterogeneity =0.941 
for ER positive and 0.866 for ER negative). Among ER positive cancers, KI67 was associated with 
worse prognosis in both node negative [2.47 (1.16 – 5.27)] and positive [1.74 (1.05 – 2.86)] tumours 
(P-heterogeneity = 0.671). Further classification according to ER, PR and HER2 showed statistically 
significant associations with prognosis among hormone receptor positive, regardless of HER2 status 
(P-heterogeneity= 0.270) and among triple negative [1.70 (1.02 – 2.84)] patients. Model fit 
parameters were similar for visual and automated measures of KI67 in a subset of 2,440 patients with 
information from both sources.  
Conclusion: Findings from this large-scale multicentre analysis with centrally generated automated 
KI67 scores show strong evidence in support of a prognostic value for automated KI67 scoring in 
breast cancer. Given the advantages of automated scoring in terms of its potential for standardisation, 
reproducibility, and throughput, automated methods appear as promising alternatives to visual scoring 
for KI67 assessment.  
Key words: breast cancer, automated KI67, visual KI67, prognostication  
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Introduction  
Despite endorsements by several international guidelines (1, 2) KI67 is yet to gain widespread 
application as a prognostic and/or predictive marker in breast cancer (3). This is due, largely, to 
methodological variability in KI67 scoring (such as antibody type, specimen type, type of fixative, 
antigen retrieval methods, method of scoring etc.), and limitations in the design and analyses of 
studies that have reported on this marker (3-7).  
In the majority of settings, KI67 is evaluated visually by a pathologist even though there is yet to be 
consensus regarding which regions to score between the invasive edge, hot spots or the entire 
spectrum of the whole section or tumour core (8). As a result, both the intra-observer and, especially, 
the inter-observer reproducibility of visually derived KI67 scores have been shown to be poor (9-11). 
This has not only hampered inter-study comparability for KI67, it has fuelled concerns regarding its 
analytical validity (3). To address some of the methodological issues related to KI67 assessment, the 
“International KI67 in Breast Cancer Working Group” published recommendations aimed at the 
standardisation of the analytical processes for KI67 evaluation (8). This panel however fell short of 
making recommendations regarding the preferred method of scoring for KI67 between visual and 
automated. Several reports suggest that automated methods could address some of the problems 
associated with visual scoring (11-19). These methods are high-throughput and not limited by intra-
observer variability. However, concerns exist regarding the accuracy of automated methods and the 
prognostic power of KI67 derived using these methods relative to that derived visually by 
pathologists. Few relatively small studies have reported a head-to-head comparison between scores 
derived using both methods in terms of prognostic properties and the results from these are conflicting 
(11, 17-19).   
The majority opinion regarding the prognostic property of KI67 derives mostly from reviews and 
meta-analyses, which support its prognostic role in breast cancer (4-7, 20). The meta-analyses by de 
Azambuja et al (6) involving 12,155 patients and another by Harris et al (7) which included over 
15,000 patients represent two comprehensive analyses on this subject. These are however limited by 
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reported evidence of publication bias, significant between-study heterogeneity, and by the fact that 
most of the included studies utilised different methodological approaches to KI67 evaluation. 
Furthermore, while the analysis by de Azambuja and colleagues (6) was limited by its inclusion of 
only univariate hazard ratios, that by Harris and colleagues (7) was limited by the small intersection 
between the sets of covariates in the included studies. In a population-based cohort of a cancer 
registry, Inwald and colleagues (21) examined the prognostic role of KI67 in 3,658 patients for whom 
KI67 was routinely measured in clinical practice and reported significant associations between KI67 
and overall survival (21). An important strength of this analysis was that it utilised routinely assessed 
KI67 measurements in a clinical setting. But this was also limited by the heterogeneity of the KI67 
analytical processes in the different laboratories involved in the study. Nonetheless, KI67 has found 
use in a variety of clinical and epidemiological scenarios including its endorsement by a number of 
international guidelines for use in treatment decision making in ER positive breast cancer (1, 2) and 
its incorporation as part of emerging prognostic tools such as the IHC4 score (22, 23) and PREDICT – 
a breast cancer treatment benefit tool (24).       
In this study, we evaluate the value and robustness of automated scoring of KI67 for large-scale, 
multicentre studies of breast cancer prognostication. We centrally generated automated KI67 score 
from stained tissue microarrays (TMAs), and assessed its prognostic value overall for different 
subtypes of breast cancer. We also compared the prognostic performance of automated and visually 
derived KI67 scores in a subset of patients. 
Materials and Methods  
Study population and study design  
This analysis was conducted within the Breast Cancer Association Consortium which is a large, 
ongoing collaborative project involving study groups across the globe (25). Figure 1 shows that we 
collected a total of 166 TMAs containing 19,039 cores, representing 10,005 patients from 13 study 
groups (supplementary Table 1). Ten study groups provided unstained TMAs which were then 
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stained and digitised in the Breakthrough Core Pathology laboratory at the Institute of Cancer 
Research (ICR) and the academic biochemistry laboratory of the Royal Marsden Hospital (RMH), 
London. Two groups (MARIE and PBCS) provided pre-stained TMAs which were also digitised in 
our centre. One study (SEARCH) provided TMA images acquired using a similar Ariol technology (a 
digital image acquisition and analysis system) to the one adopted for this analysis. Of the 10,005 
patients, 1,917 were excluded on account of failing predefined quality control checks (N = 946) or 
due to absent data on follow-up times and/or vital status (N = 971). As a result, a total of 8,088 
patients from 10 study groups with a median follow-up of 7.5 years and a total of 1,401 breast cancer 
specific deaths were used in the survival analysis involving automated KI67. Of these, 2,440 patients 
with pathologists’ visual in addition to automated KI67 scores were used to extrapolate a visual from 
an automated cut-off point, following which comparative survival analyses involving visual and 
automated KI67 scores were conducted. Information on other clinico-pathological characteristics of 
tumours including histological grade, nodal status, tumour size, stage, adjuvant systemic therapy 
(endocrine therapy and/or chemotherapy) and other IHC markers i.e. oestrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) were obtained 
from clinical records. Additional Ariol HER2 data were obtained for a subset of patients with missing 
clinical HER2 data but for whom data on ER and PR were available (N = 403). All patients provided 
written informed consent and all participating studies gained approval from the local Ethical 
Committees and Institutional Review Boards.       
KI67 immunostaining  
Sections were dewaxed using xylene and rehydrated through graded alcohol (100, 90, and 70%) to 
water. Slides were then placed in a preheated (5 mins 800W microwave) solution of Dako Target 
Retrieval solution pH6.0 (S1699) and microwaved on high power for 10mins and then allowed to cool 
in this solution at room temperature for ten minutes. In the next stage, the slides were placed on a 
Dako autostainer and stained using a standard protocol using Dako MIB-1 diluted 1/50 and visualised 
using the Dako REAL kit (K5001). The MIB-1 antibody was also adopted for the staining of those 
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TMAs that were not part of those centrally stained at the ICR but at varying concentrations (PBCS = 
1:500; MARIE = 1:400 and SEARCH = 1:200) (supplementary Table 2).  
KI67 scoring  
This has been previously described (26), but briefly: all TMA’s were digitised using the Ariol 50s 
digital scanner. Fifteen TMAs were selected as a training set. These were scored visually by a 
pathologist (MA) using a computer-assisted visual (CAV) counting method and used to validate the 
automated method. The CAV method relied upon built-in features of the Ariol digital system to count 
negative and positive nuclear populations within 250µm by 250µm squares separated by grids. The 
standard CAV approach entailed the counting of at least 1,000 cells across the entire spectrum of each 
core. In the majority of cores, more than 1,000 cells were counted even though fewer than this number 
was counted in a small minority. Overall, cores with more than 500 cells were considered to be of 
satisfactory quality. The CAV method is precise, prevents double counting and was observed to have 
excellent intra-observer reproducibility when a random subset of cores (N = 111) were re-scored at an 
interval of three months from the first time they were scored (observed agreement/kappa = 96%/0.90); 
good core-level agreements with two other independent scorers (observed agreement/kappa: CAV vs 
scorer 2 = 87%/0.66; CAV vs scorer 3 = 84%/0.59; scorer 2 vs. scorer 3 = 89%/0.69) were also 
observed in a randomly selected subset of 202 cores. Visual scoring in the external TMAs involved 
both quantitative and semi-quantitative methods. Each core from each patient was scored by two 
independent pathologists and the KI67 score for each patient was then taken as the average score from 
the two scorers across all the cores for that patient. 
The automated scoring was performed using the Ariol machine which has functionality that allows for 
the automatic detection of malignant and non-malignant nuclei using shape and size characteristics. 
Using colour deconvolution, it also distinguishes between DAB positive and negative (haematoxylin) 
malignant cells. To determine the negative and positive populations of cells, an appropriate region of 
interest of the malignant cell population in a core was demarcated and two colours were selected to 
indicate positive and negative nuclear populations. The appropriate colour pixels were then selected to 
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represent the full range of hue, saturation and intensity that was considered representative of the 
positive and negative nuclear classes (26). Subsequently, the best shape parameters that discriminated 
malignant and non-malignant cells according to their spot width, width, roundness, compactness and 
axis ratio were then also selected. The data were divided into a training and a validation subset and the 
automated and visual scoring for KI67 showed good agreement (observed agreement = 87%; Kappa = 
0.64) and discriminatory accuracy (AUC = 85%) in the validation subset hence allowing for the 
adoption of this method for the scoring of all 166 TMA’s.  
Statistical methods 
For patients with multiple cores from the same tumour, we used the average KI67 score across valid 
cores to represent the % positive cells in that tumour. Descriptive analyses of the distribution of KI67 
according to clinical and pathological characteristics of the patients were conducted using the non-
parametric Kruskal-Wallis equality of medians test for continuous measures and the paired chi-
squared test for categorical measures. The relative survival probabilities for patients in different 
quartiles of the KI67 distribution were compared using Kaplan-Meier survival curves for the 10-year 
breast cancer specific survival (BCSS). To allow for prevalent cancers, time at risk was left-censored 
for study entry. It was decided, a priori, to not make any assumptions on a prognostic cut-off point for 
automated KI67 scores in our dataset but to, instead, leverage on the continuous values to observe a 
prognostic threshold. As a result, we performed quartile analysis by dividing the continuous KI67 
scores into quartiles (Q1-Q4) and examining the prognostic differences among the different quartiles 
for all the patients in the study. The 10-year BCSS was determined in Kaplan-Meier survival curves 
and in Cox-proportional hazards regression models stratified by ER status (positive vs negative) and 
according to nodal status (positive vs negative) and other IHC markers. The univariate Cox models 
were partially adjusted for study group and age at diagnosis while the multivariate models had further 
adjustments for other known prognostic factors including histological grade, tumour size, nodal status, 
morphology, ER, PR, HER2 and adjuvant systemic therapy (endocrine and/or chemotherapy). In the 
multivariate models, missing values on other covariates were addressed using the multiple imputation 
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plus outcome (MI+) approach (27). Due to observed violation of the proportionality assumption of the 
Cox model by automated KI67, it was modelled as a time varying covariate using an extension of the 
Cox model that allows for the inclusion of a coefficient (T) that varied as an exponential function of 
time. The log of the coefficient is indicative of both the direction and the magnitude of change in 
hazard ratio with time, such that if log T is <1 hazard falls with time while if it is >1 hazard increases 
with time. Known violation of the proportional hazards assumption by ER was addressed in the same 
way. Consistency of hazard ratio (HR) estimates across the different study groups was evaluated using 
the I
2
 statistic, derived by performing a fixed-effect meta-analysis of study-specific HR estimates. To 
enable direct comparison between the visual and automated KI67 scores, we extrapolated a visual 
from an automated cut-off point in a linear regression model and used the resulting cut-off point for 
all further analyses. All analyses were conducted using STATA statistical software version 10 
(StataCorp, 4905 Lakeway drive, College Station, Texas). Statistical tests were two-sided and p-
values less than 0.05 were considered to be statistically significant. 
Results  
Description of study population and association between automated KI67 score and other 
clinico-pathological characteristics of breast cancer patients (N = 8,088)   
In all, a total of 143 TMAs containing 15,313 cores from 8,088 patients were used in this analysis as 
shown in Figure 1. The studies included in this analysis used different TMA designs (Table 1).  More 
than half (4,431/55%) of the patients had KI67 scores on at least two cores and evaluation of 
dichotomous categories revealed concordant KI67 status in 83.7% of the patients. When we examined 
the distribution of continuous KI67 scores among categories of the different clinical and pathological 
characteristics we observed this to differ according to histological grade, tumour size, morphology, 
ER status, PR status, and HER2 status but not nodal status or stage at diagnosis (Figure 2). The 
distribution of these characteristics for patients with high (Q4 or >12% positive cells) and low (Q1-
Q3) KI67 are shown in Supplementary Tables 3 and 4 for ER positive and ER negative patients, 
respectively.  
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Association between automated KI67 score and 10-year BCSS among 8,088 patients  
Using continuous measures of KI67 categorised into quartiles, we observed poorest survival in the 
highest quartile, corresponding to 12% positive cells, but little difference in survival between the 
other three (Q1-Q3) quartiles (log-rank P = 1.2×10
-5
; Figure 3A). As a result, the continuous KI67 
value was dichotomised at the threshold of 12% in subsequent analyses. High KI67 was significantly 
associated with 10-year BCSS overall (log-rank P = 3.1×10
-7
) among ER positive (log-rank p-value = 
1.3×10
-3
) but not ER negative (log-rank P = 0.35) cancers (Figure 3, B, C and D, respectively). 
Similarly, in multivariate models, high KI67 expression was significantly associated with worse 10-
year BCSS among ER positive (HR at baseline = 1.96; 95% CI = 1.31 – 2.93) but not ER negative 
breast cancers (HR = 1.23; 95% CI = 0.86 – 1.77; P-heterogeneity = 0.064) (Table 2). Further 
stratification of ER positive cancers according to nodal status showed that high KI67 was associated 
with worse survival in both node negative and node positive cancers in  multivariate analysis [Node 
negative (2.47 (1.16 – 5.27)); Node positive (1.74 (1.05 – 2.86)); P-heterogeneity = 0.67] (Table 2). 
The association between KI67 and survival was significant among ER positive patients who did not 
receive chemotherapy [1.95 (1.18 – 3.21); p-value = 0.009] but not among those who did [1.89 (0.84 – 
4.29); p-value = 0.124; P-heterogeneity = 0.60]. We found no evidence of between study 
heterogeneity in estimates of HR for ER positive (I
2
 = 0.0%, P = 0.94) or ER negative (I
2
 = 0.0%, P = 
0.86) patients (supplementary Figure 1). Among hormone receptor positive breast cancers, the HR 
for KI67 was not significantly different according to HER2 status (Table 2; P-heterogeneity = 0.270). 
Modest evidence for a poorer prognosis among high, relative to low, KI67 was also seen for triple 
negative breast cancers [1.70 (1.02 – 2.84); P = 0.04]. No significant associations with prognosis were 
found for KI67 among HER2-positive (i.e. ER-/PR-/HER2+) [0.91 (0.60 – 1.36)] breast cancers 
(Table 2).  
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Comparison of 10-year BCSS among 2,440 patients with both visual and automated 
quantitative KI67 scores 
The automated cut-off point of 12% positive cells corresponded to a visual cut-off point of 24.2% 
based on a linear regression model comprising patients with quantitative data on both methods. The 
visual cut-off was rounded up to a cut-off point of 25%. Strong evidence (p-value <0.0001) in support 
of a positive linear correlation (r = 0.63) between automated and visual scores was observed and 
continuous automated scores showed good discriminatory accuracy against the visually determined 
binary classes (AUC = 82%, 95%CI = 80 – 84%). 26% of the patients were classified as having high 
visual KI67 in contrast to 29% for the automated KI67 scores; cross classification of visual and 
automated categories revealed better specificity (84%) than sensitivity (65.6%) for the automated 
score in classifying visually determined categories (Supplementary Table 5). High KI67 was 
associated with worse survival in Kaplan-Meier curves based on both automated (log-rank p-value = 
9.8×10
-6
) and visual (log-rank p-value = 3.8×10
-14
) KI67 even though attenuation of the difference 
between strata was observed for automated KI67 scores (Supplementary Figure 3). In two separate 
models for visual and automated KI67 each adjusted for age at diagnosis and study group we 
observed stronger evidence for an association between KI67 and survival for visual than automated 
KI67 (Table 3). Analysis of model fit however revealed similar parameters for both scores especially 
in ER positive breast cancers (AIC/BIC: visual = 2656/2618 and automated 2675/2638) (Table 3). 
When we performed further adjustments for other prognostic factors in multivariate Cox models of 
imputed datasets, we observed both visual and automated KI67 scores to be significantly associated 
with survival for all patients [HR (95%CI): visual = 1.75 (1.23 – 2.49); automated = 1.61 (1.14 – 
2.28)] and in ER positive [visual = 2.30 (1.34 – 3.94); automated = 2.10 (1.28 – 3.47)] but not ER 
negative [visual = 1.63 (0.97 – 2.72); automated = 1.28 (0.79 – 2.05)] patients (Table 3).  
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Discussion  
Findings from our analysis provide strong evidence in support of a prognostic relationship for 
automated KI67 scoring in ER positive (node negative and node positive) patients that is independent 
of tumour grade and other prognostic factors. Even though our data suggested a larger magnitude of 
the association between KI67 and survival among the node negative patients, the difference between 
node positive and negative was not statistically significant. With over 8,000 patients from multiple 
centres internationally, this represents the largest study that has evaluated the prognostic value of 
automated KI67 scoring in breast cancer till date. Furthermore, the large sample size allowed us to 
evaluate its prognostic value in a number of breast cancer subtypes including ER+ (node negative and 
positive), ER–, ER+ and/or PR+ (HER2+ or HER2–), ER–/PR– and HER2+ (i.e. HER2-enriched) and 
triple negative breast cancers.   
Our findings suggest that automated KI67 scoring is an analytically valid approach to generating KI67 
scores. This is particularly noteworthy given the growing need to incorporate measures of KI67 in 
prognostic tools such as the IHC4 score and PREDICT (23, 24). These tools are relatively cheap, 
readily available, and utilise routinely measured IHC markers and, in the case of PREDICT, other 
routinely available patient data to provide information that can help clinicians and patients make 
informed decisions regarding the course of treatment. It is acknowledged that prognostication in 
breast cancer is becoming increasingly more sophisticated and that a number of multigene assays (28, 
29) have been validated for this purpose, however, their costs and proprietary concerns limit their use 
in a large number of settings. Moreover, findings from previous studies suggest that some multigene 
assays may not perform better than routinely measured IHC markers. For instance, Cuzick et al (23) 
reported similar prognostic properties for the Genomic Health recurrence score (GHI-RS, Oncotype 
DX), a 21 gene panel test, and the IHC4 score in their analysis of 1,125 women from the TransATAC 
study and notably KI67 was assessed by image analysis in that study (23). Nonetheless, the relative 
performance of visual and automated KI67 scores in relation to the IHC4 score or PREDICT can only 
be assessed in studies that are specifically designed for that purpose.    
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In addition to lack of analytical validity, the prognostic performance of KI67 has also been questioned 
due to the design and analysis of studies that have previously reported on this protein (3). Ours is a 
large scale, multicentre analysis which has adopted the recommended laboratory processes for the 
staining and scoring of KI67 (8). All TMAs in our analysis were stained using the MIB1 antibody 
(even though not all of them were centrally stained in our centre) and scored using a single automated 
algorithm. Our estimates of a ~2-fold and ~1.5-fold increased risk of mortality at baseline for high 
versus low KI67 in univariate and multivariate analyses, respectively, are similar to those reported by 
de Azambuja et al (HR = 1.95) and Harris et al (HR = 1.42) in their univariate and multivariate meta-
analyses, respectively (6, 7). Stratification of our analysis according to other IHC markers (in addition 
to ER) showed automated KI67 to be prognostic in hormone receptor positive cancers. These 
findings, together with our observation of the prognostic value of KI67 in both node negative and 
node positive ER positive patients, support the decision by the St Gallen international Expert 
Consensus to endorse KI67 for treatment decision making in ER positive early (1-3 axillary nodes) 
breast cancer patients (1). We also observed modest evidence in support of poorer survival outcomes 
among high, relative to low, KI67 expressing triple negative subtypes of breast cancer. This finding is 
in support of a previous report by Keam and colleagues (30). Our population of triple negative breast 
cancers (N=1,001) was however 9.5 times larger than that of Keam et al (N = 105).   
Comparative analysis of visual and automated KI67 scores showed a stronger survival association for 
the visual over the automated scores; however, differences were generally modest. Given the 
advantages of automated versus visual scoring in terms of its potential for standardisation, 
reproducibility, and throughput, automated methods appear as promising alternatives to visual scoring 
for KI67 assessment. A potential limitation to the adoption of automated KI67 scoring in the clinical 
setting is that misclassification of positive as negative nuclei, or malignant as benign nuclei could lead 
to attenuation of prognostic associations, an observation that has been previously reported for ER and 
PR (31) and one which we have also observed for KI67 in this analysis. This can however be 
mitigated by stringent quality control processes or by the adoption of a synergistic approach that 
combines the benefits of both the automated and visual scoring methods. One such approach is the 
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CAV scoring method which we developed for the visual counting of negative and positive malignant 
nuclei. This approach, a variation of which has been previously reported (15), exploits the advantages 
of both visual and digital imaging tools by enabling the visual counting of KI67 positive cells in well-
defined areas of a tumour within a computer microenvironment. This method is however limited by 
the observation that it is time consuming; as such, it may not be efficient if adopted for the large-scale 
scoring of KI67 in epidemiological studies, clinical trials or biomarker discovery studies. Nonetheless, 
efforts are currently underway to standardise the methods for the visual scoring of KI67 in core-cuts.  
We centrally generated KI67 scores on TMAs and determined a threshold of 12% positive cells of 
prognostic relevance in our study population. However, due to possible variations in the distribution 
of KI67 scores according to specimen type and among different laboratories, this cut-off point may 
not apply to other types of clinical samples or to other laboratories. As a result, pending international 
standardisation of the KI67 analytical processes, setting local laboratory-specific cut-off points as 
recommended by international guidelines (1) remains a pragmatic approach to determining ‘high’ and 
‘low’ KI67. Furthermore, although our automated cut-off point of 12% positive cells was determined 
to correspond to a visual score of 25%, this may be related, at least in part, to the fact that automated 
systems generally count more cells than the visual evaluator, a reason that has been proposed to 
explain differences in KI67 scores between visual and automated scoring and between different 
automated scoring approaches (26). Nonetheless, findings from a recent meta-analysis that assessed 
the prognostic value of different cut-off levels of KI67 suggest that a visual cut-off point of >25% 
provides greater discrimination in mortality risk than other cut-off points (32).                 
Some limitations of our analysis include the lack of data on specific chemotherapeutic or endocrine 
agents received by each patient, as a result of which we were unable to account for the impact of 
specific treatment regimen on survival or to examine whether or not KI67 is predictive of response to 
specific chemotherapeutic and/or endocrine agents. We were however able to account for whether or 
not patients received adjuvant systemic treatment in all our analyses as more than two-thirds of the 
patients had information on treatment. This also allowed us to perform stratified analysis according to 
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whether or not chemotherapy was administered. Also, we did not have data on disease free survival 
which may have been a more informative end point than BCSS in early breast cancer. Our assessment 
of KI67 on TMAs may mean that direct inference cannot be drawn from our findings on other types 
of clinical samples, especially whole sections (8). This is because KI67 scores are speculated to be 
lower for TMAs than for whole sections and not many studies have assessed the correlation between 
KI67 scores on TMAs and those on whole sections. However, one such study by Kobierzycki and 
colleagues involving 51 archival paraffin blocks of invasive ductal carcinoma showed excellent 
correlation (r = 0.91) between the TMAs and whole sections (33). Their paper however utilised three 
0.6 mm core punches and this may explain the high correlation between KI67 scores on TMAs and 
whole sections that was observed in that study. Nonetheless, the fact that more than half (4,431/55%) 
of the patients in our analysis had KI67 scores on two or more cores with 83% of these showing 
concordant KI67 status should limit the impact of intra-tumour heterogeneity of KI67 scores on our 
findings.  
Conclusion 
Our large, multicentre study indicates that automated KI67 scoring provides prognostic information in 
breast cancer that is independent of standard parameters. In view of its potential for standardisation, 
throughput and reproducibility, the automated method appears to be a promising alternative to visual 
scoring for KI67. These findings are important given the increasing need to incorporate measures of 
KI67 as part of tools that are needed to refine prognostic scores for breast cancer patients; this is 
especially relevant for patients with ER-positive, node negative tumours, in order to aid decisions on 
providing adjuvant chemotherapy. However, further work is needed to standardise the staining and 
scoring protocols for KI67. In doing so, the potential benefits and drawbacks of automated versus 
visual scoring systems should merit consideration. It is in light of this that we welcome ongoing 
efforts by the International Working Party on KI67 in Breast cancer aimed at standardisation of the 
analytical processes for KI67.    
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Table 1: Description of study populations, TMA designs and patient characteristics for the 8,088 patients included in this analysis 
 
Study Acronym Country  Cases (N)  Age at diagnosis TMAs Cores/patient  Cores/patient Cores  Core size Total cores  
      Mean (range)    (range) (average)  per TMA in mm per study 
ABCS Netherlands  885 43 (19-50) 24 1-6 2.77 15-328 0.6 2,449 
ESTHER Germany  252 62 (50-75) 6 1-2 1.83 78-91 0.6 461 
KBCP Finland  266 59 (30-92) 12 1-3 2.72 63-94 1.0 724 
MARIE Germany  808 62 (50-75) 27 1-5 1.84 32-92 0.6 1,490 
MCBCS USA 437 58 (22-87) 7 1-8 3.73 131-301 0.6 1,630 
ORIGO Netherlands  348 53 (22-87) 9 1-9 2.85 67-223 0.6 991 
PBCS Poland  1,068 56 (27-75) 22 1-2 2.21 66-145 1.0 2,358 
RBCS Netherlands  225 45 (25-84) 6 1-5 2.85 134-199 0.6 642 
SEARCH United Kingdom 3,491 52 (24-70) 24 1-3 1.16 120-167 0.6 4,037 
kConFab Australia/New Zealand  308 45 (20-77) 6 1-2 1.72 65-114 0.6 531 
Total   8,088 53 (19-92) 143 1-9 1.89 15-328 0.6-1.0 15,313 
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Table 2: Hazard ratios (HR) and 95% CI for the association between automated KI67 score and 
10-year BCSS in partially and fully adjusted models: Analysis stratified overall and according 
to ER, nodal status and other IHC markers (N = 8,088 patients).  
      Partially adjusted
1
 Fully adjusted
2
* 
  Patients (N) Deaths (N) HR (95%CI) p-value HR (95%CI) p-value 
All cancers       
Low KI67 6,093 1,030 1.00 (referent)  1.00 (referent)  
High KI67 1,995 371 2.32 (1.79, 3.00) 6.34×10
-11
 1.47 (1.13, 1.92) 0.004 
T
3
   0.89 (0.84, 0.94) 3.20×10
-05
 0.93 (0.87, 0.98) 0.010 
       
ER positive       
Low KI67 4,379 615 1.00 (referent)   1.00 (referent)   
High KI67 1,141 166 2.47 (1.63, 3.72) 8.45×10
-06
 1.96 (1.31,  2.93) 0.001 
T 
  
0.88 (0.81, 0.96) 0.003 0.89 (0.82,  0.97) 0.006 
     
ER negative       
Low KI67 1,271 320 1.00 (referent)  1.00 (referent)  
High KI67 778 188 1.38 (0.97, 1.97) 0.072 1.23 (0.86, 1.77) 0.248 
T 
  
0.94 (0.86, 1.02) 0.155 0.94 (0.87, 1.03) 0.199 
     
ER positive/Node positive       
Low KI67 1,550 350 1.00 (referent)   1.00 (referent)   
High KI67 408 94 2.22 (1.31, 3.77) 0.003 1.74 (1.05, 2.86) 0.031 
T   0.91 (0.82, 0.99) 0.044 0.91 (0.82, 1.01) 0.075 
       
ER positive/Node negative       
Low KI67 2,399 205 1.00 (referent)  1.00 (referent)  
High KI67 561 55 3.17 (1.43, 6.99) 0.004 2.47 (1.16, 5.27) 0.019 
T   0.84 (0.71, 0.98) 0.034 0.86 (0.73, 0.99) 0.048 
       
HRP/HER2-       
Low KI67 3,332 462 1.00 (referent)   1.00 (referent)   
High KI67 831 114 1.69 (1.26, 2.27) 2.42×10
-04
 1.49 (1.10, 2.00) 0.009 
T   0.94 (0.90, 0.98) 0.004 0.94 (0.90, 0.98) 0.004 
       
HRP/HER2+
 
      
Low KI67 421 82 1.00 (referent)  1.00 (referent)  
High KI67 157 36 1.96 (1.28, 3.00) 9.70×10
-04
 1.59 (1.03, 2.45) 0.035 
T   0.94 (0.90, 0.98) 0.004 0.94 (0.90, 0.98) 0.004 
       
HRN/HER2- (Triple negative) 
  
        
Low kI67 565 142 1.00 (referent)   1.00 (referent)   
High KI67 436 107 1.75 (1.06, 2.90) 0.028 1.70 (1.02, 2.84) 0.044 
T 
  
0.86 (0.75, 0.98) 0.031 0.86 (0.75, 0.99) 0.031 
     
HRN/HER2+ (HER2-enriched)       
Low KI67 227 85 1.00 (referent)  1.00 (referent)  
High KI67 149 48 0.76 (0.37, 1.55)  0.450 0.75 (0.36, 1.57) 0.455 
T   1.08 (0.90, 1.29) 0.396 1.07 (0.90, 1.29) 0.435 
1Partially adjusted models – adjusted for age at diagnosis and study group 
2Fully adjusted models – further adjustment for histological grade, tumour size, nodal status, morphology, PR, HER2, systemic therapy 
(endocrine and/or chemotherapy) and (for the model involving all patients) ER status. *This model was based on 20 imputations performed 
to address missing values on other covariates 
3T = log of time varying coefficient (if T <1 hazard falls with time and if T >1 hazard increases with time).  
HRP = Hormone Receptor Positive  
HRN = Hormone Receptor Negative  
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Table 3: Univariate (partially adjusted) and multivariate (fully adjusted) hazard ratios (HR) and 95% CI for the associations between automated 
and visual KI67 scores with survival in breast cancer (N = 2,440)  
      
1
 Partially adjusted model 
2
 Fully adjusted model* 
  Visual    Automated  Visual   Automated  
  Patients Deaths HR (95%CI) p-value   Patients Deaths HR (95%CI) p-value HR (95% CI) p-value   HR (95% CI) p-value 
Overall                             
Low KI67 1,804 116 1.00 (Ref)     1,728 125 1.00 (Ref)   1.00 (Ref)     1.00 (Ref)    
High KI67 636 78 2.40 (1.92, 3.01) 2.20×10
-14
   712 69 1.67 (1.33, 2.10) 1.30×10
-05
 1.75 (1.23, 2.49) 0.002   1.61 (1.14, 2.28) 0.007 
AIC
ⱡ
     5050.4         5087.2             
BIC
ⱡ
     5090.8         5127.6             
ER positive                             
Low KI67 1,337 69 1.00 (Ref)     1,241 69 1.00 (Ref)   1.00 (Ref)     1.00 (Ref)   
High KI67 282 27 2.40 (1.72, 3.33) 2.00×10
-07
   378 27 1.47 (1.05, 2.04) 0.024 2.30 (1.34, 3.94) 0.002   2.10 (1.28, 3.47) 0.004 
AIC     2618.8         2638.2             
BIC     2656.8         2675.8             
ER negative                             
Low KI67 357 39 1.00 (Ref)     392 48 1.00 (Ref)   1.00 (Ref)     1.00 (Ref)   
High KI67 331 48 1.84 (1.30, 2.62) 6.10×10
-04
   296 39 1.44 (1.02, 2.04) 0.043 1.62 (0.97, 2.72) 0.066   1.28 (0.79, 2.05) 0.312 
AIC     1755.7         1763.4             
BIC     1787.4         1795.1             
1 Partially adjusted model – adjusted for age at diagnosis and study group only 
2 Fully adjusted model – further adjustment for other prognostic factors including histological grade, tumour size, nodal status, ER, PR, HER2, morphological subtype, and systemic therapy 
(endocrine and/or chemotherapy). *This model was based on 20 imputations performed to address missing values on other covariates. 
ⱡ Model fit parameters: AIC – Akaike information criterion; BIC – Bayesian information criterion.  
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Figure legends 
Figure 1: Study population and study design  
We collected 166 TMAs containing 19,039 cores from 10,005 patients. Of these, 15 TMAs containing 
1,346 cores were selected as the training set and these were used to develop an automated scoring 
protocol that was validated against corresponding computer-assisted visual (CAV) scores. Ultimately, 
this protocol was applied to the scoring of all 166 TMAs. Following automated scoring, all cores that 
failed our priori defined quality control checks (including total nuclei count >50 and <15,000, and 
KI67 score = 100%) were excluded (N = 946 patients). For the purpose of survival analyses, all 
subjects with missing follow-up/survival data were also excluded (N = 971 patients). As a result, a 
total of 8,088 patients were used in the survival analysis involving automated KI67 score. 
Furthermore, based on a subset of patients (N = 2,440) with pathologists’ in addition to the automated 
KI67 scores, we extrapolated a visual from an automated cut-off point and used this to compare the 
prognostic performance of visual and automated KI67 scores in breast cancer.   
Figure 2: Distribution of continuous KI67 scores according to categories of other clinical and 
pathological variables. Significant differences were seen in the distribution of automated KI67 
scores according to categories of histological grade, tumour size, morphology, ER status, PR status, 
and HER2 status but not nodal status or stage.  
Figure 3: Kaplan-Meier survival curves for the 10-year BCSS according to strata of automated 
KI67 scores, overall and by ER status.  
KM survival curves for the association between KI67 and 10-year BCSS among (A) Quartiles of KI67 
(Q1 = <25
th
 percentile; Q2 = 25
th
 – 50th percentile; Q3 = >50th – 75th percentile and Q4 = >75th 
percentile; N = 8,088); (B) Dichotomous categories of KI67 (≤12/low and >12%/high), overall (N = 
8,088 patients); (C) ER positive cancers (N = 5,520 patients); and (D) ER negative cancers (N = 2,049 
patients).   
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Supplementary Materials 
Supplementary Figure 1: Meta-analysis of study specific hazard ratios (HR) stratified by ER status 
Supplementary Figure 2: ROC curve for the discriminatory accuracy of continuous automated KI67 
scores against binary visual categories (≤ 25% and > 25%) based on a subset of patients with data on 
both visual and automated KI67 scores.  
Supplementary Figure 3: Kaplan-Meier survival curves for the 10-year BCSS according to strata 
(high and low) of automated and visual KI67 scores (N = 2,440) 
Supplementary Table 1: Description of study populations  
Supplementary Table 2: KI67 immunohistochemistry reagents and antigen retrieval protocols 
according to study groups  
Supplementary Table 3: Association of clinical and pathological characteristics with high (>12%) 
and low (≤12%) KI67 categories among 5,520 ER positive breast cancer cases  
Supplementary Table 4: Association of clinical and pathological characteristics with high (>12%) 
and low (≤12%) KI67 categories among 2,049 ER negative breast cancer cases  
Supplementary Table 5: Cross classification of visual and automated KI67 score categories 
Supplementary Table 6: Multivariate model for the association of KI67 with 10-year BCSS among 
5,520 ER positive patients 
Supplementary Table 7: Multivariate model for the association of KI67 with 10-year BCSS among 
2,049 ER negative patients  
